Folate-Tweaked Chitosan Nanoparticles Emerge as Precision Cancer Delivery Workhorses

Cancer chemotherapy has long been a blunt instrument. Drugs that can kill tumor cells also ravage healthy tissue, and the body clears many of them so quickly that patients must endure high, toxic doses just to give the medicine a fighting chance at the tumor site. A new review published in Medical Oncology by Mohammad Sameer Khan of Jamia Hamdard and Waleed Hassan Almalki of Umm Al-Qura University takes stock of one of the most quietly promising answers to this problem: nanoparticles built from chitosan, a sugar-derived biopolymer, and decorated on their surface with folate, the vitamin better known as folic acid. The pairing sounds almost too simple, but it exploits a genuine biological loophole that many tumors leave wide open.

The loophole is the folate receptor, a cell-surface protein whose normal job is to snag vitamin B9 from the bloodstream and pull it inside the cell. In a range of malignancies, including breast, ovarian, lung, colorectal, pancreatic, and cervical cancers, tumor cells crank up production of this receptor to feed their rapid division. By chemically attaching folate to the surface of a chitosan nanoparticle, drug designers create a particle that cancer cells actively import through folate receptor-mediated endocytosis, the same process the cells use to harvest the vitamin itself. The result is a delivery vehicle that does not merely drift into tumors passively but is actively swallowed by the malignant cells, concentrating the toxic payload where it is needed and sparing healthy tissue that expresses little of the receptor.

Chitosan itself brings an unusually attractive set of properties to the partnership. Extracted from chitin, the structural polymer of crustacean shells, it is biocompatible, biodegradable, and positively charged at physiological pH, which allows it to form stable nanoparticles through mild, water-based chemistry rather than harsh organic solvents. It is also mucoadhesive, meaning it clings to biological surfaces, and chemically versatile, with amine groups along its backbone that provide convenient handles for attaching targeting ligands like folate. The review emphasizes that this chemical versatility is what makes the platform so adaptable: researchers can tune particle size, surface charge, and drug-loading capacity by adjusting the degree of deacetylation of the polymer, the molecular weight of the chitosan chains, and the density of folate conjugation on the surface.

The published literature assembled in the review shows how broadly this design has already been tested in laboratory and preclinical settings. Folate-conjugated chitosan nanoparticles have been loaded with 5-fluorouracil for site-targeted colorectal delivery, with cytarabine for improved killing of MCF-7 breast cancer cells, with dasatinib for folate receptor targeting, with gemcitabine for lung cancer, and with paclitaxel for ovarian cancer cells. Natural compounds have joined the roster as well, including thymoquinone aimed at ovarian cancer, curcumin analogues, osthole delivered to pancreatic and colon cancer models, and an apolar acetogenin that inhibits cervical cancer cell proliferation. In many of these studies, the folate-targeted formulation outperformed its non-targeted counterpart in cellular uptake, cytotoxicity, and sustained drug release, precisely the profile that precision oncology demands.

Several studies highlighted in the review push the platform beyond simple one-drug, one-target designs. Folate-tagged chitosan-functionalized gold nanoparticles have been used to deliver doxorubicin to breast and cervical cancer cells and 5-fluorouracil to folate receptor-positive tumors. Chitosan-folate decorated carbon nanotubes have been engineered for site-specific lung cancer delivery, and folic acid-conjugated magnetic oleoyl-chitosan nanoparticles allow doxorubicin to be released in a controlled fashion while the magnetic core opens the possibility of image-guided delivery. Dual-drug systems are also appearing, such as folate-targeted chitosan nanoparticles co-delivering 5-fluorouracil and methotrexate, exploiting the synergy between two antimetabolites. Stimuli-responsive variants add another layer of sophistication: glutathione-responsive, folate receptor-targeted nanoparticles have been designed to unload their cargo only after entering the reducing environment of the tumor cell interior, and pH-responsive folate-conjugated chitosan systems exploit the acidity of the tumor microenvironment to trigger release specifically at the disease site.

The review also situates folate-chitosan systems within the broader movement toward smart, multifunctional nanocarriers, pointing to recent work on MXene quantum dot polymer nanocomposites as an example of where the field is heading. The common threads, the authors argue, are surface engineering, multifunctionality, controlled release, and rigorous safety evaluation. A modern nanocarrier is expected not just to carry a drug but to respond to its surroundings, potentially carry a diagnostic agent alongside the therapeutic payload, and degrade into harmless byproducts. Chitosan’s track record in this respect is strong: it is already used in approved medical products, and clinical trial analyses of chitosan-based biomaterials suggest a regulatory pathway that many exotic nanomaterials lack.

Pharmacokinetics and biodistribution are where targeted nanocarriers must ultimately prove themselves, and the review addresses these dimensions directly. Compared with non-targeted formulations, folate-functionalized chitosan nanoparticles have the potential to enhance cellular uptake, provide sustained and controlled drug release, improve anticancer efficacy, and reduce systemic toxicity. The active targeting mechanism complements the enhanced permeability and retention effect, the passive tendency of nanoparticles to accumulate in leaky tumor vasculature, by adding a receptor-driven import step once the particles reach the tumor. This dual mechanism, passive accumulation followed by active cellular uptake, is one reason the platform has attracted sustained attention across so many tumor types.

Yet the review is notably candid about the obstacles standing between the laboratory bench and the oncology clinic. Reproducibility of nanoparticle synthesis remains a stubborn problem, as small batch-to-batch variations in polymer properties can alter particle behavior in clinically meaningful ways. Formulation stability during storage, immunogenicity concerns, and scalability of manufacturing all require careful attention before regulatory agencies will approve a folate-chitosan product. Perhaps the most biologically thorny challenge is interpatient variability in folate receptor expression: the entire targeting strategy depends on the tumor displaying the receptor, and expression levels differ between patients, between tumor types, and even between regions of the same tumor. The authors argue that successful clinical development will require careful attention to all of these translational challenges, not just the elegant chemistry of the particles themselves.

What emerges from the review is a picture of a platform that is biologically relevant, chemically tunable, and increasingly sophisticated, but still awaiting its decisive clinical test. The preclinical evidence base is broad, spanning conventional cytotoxics, repurposed drugs, and natural products, and the safety profile of the underlying polymer is well characterized. If the fields of formulation science and regulatory science can catch up with the chemistry, folate-modified chitosan nanocarriers could move from a versatile laboratory tool to a genuine instrument of precision oncology, delivering lethal payloads to the cells that display the right molecular address while leaving the rest of the body largely untouched.

Subject of Research: Folate-functionalized chitosan nanoparticles for targeted anticancer drug delivery

Article Title: Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives

Article References: Khan, M. S., & Almalki, W. H. (2026). Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives. Medical Oncology, 43(10), Article 282. https://doi.org/10.1007/s12032-026-03415-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03415-2

Keywords: chitosan nanoparticles, folate receptor, targeted drug delivery, precision oncology, nanomedicine, chemotherapy, drug delivery, biodegradable polymers, cancer therapy, endocytosis, controlled release, clinical translation